Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) shares rose 4.1% during trading on Wednesday . The stock traded as high as $1.73 and last traded at $1.63. Approximately 3,139,503 shares traded hands during mid-day trading, a decline of 3% from the average daily volume of 3,225,500 shares. The stock had previously closed at $1.70.

Separately, Maxim Group initiated coverage on Interpace Diagnostics Group in a research note on Tuesday, August 15th. They issued a “buy” rating and a $5.00 price objective for the company.

The company’s 50-day moving average is $1.13 and its 200-day moving average is $1.79. The stock’s market capitalization is $35.24 million.

Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings results on Thursday, August 10th. The business services provider reported ($0.65) earnings per share for the quarter. Interpace Diagnostics Group had a negative return on equity of 32.06% and a negative net margin of 37.08%. The company had revenue of $3.86 million during the quarter.

A hedge fund recently bought a new stake in Interpace Diagnostics Group stock. Susquehanna International Group LLP purchased a new position in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned about 3.84% of Interpace Diagnostics Group as of its most recent SEC filing. Hedge funds and other institutional investors own 7.58% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.